UNION therapeutics

Feb 21, 2025

UNION therapeutics announces presentation of preliminary data from Phase 2a investigator-initiated study with orismilast in ulcerative colitis at the 20th ECCO Congress

Jun 04, 2024

UNION therapeutics announces successful completion of the ADESOS Phase 2b study and presentation of data at the RAVE Conference 2024

Oct 28, 2020

UNION therapeutics appoints Dr. Kim Kjoeller as Chief Executive Officer and further strengthens leadership by appointing Dr. Günter Ditzinger as Chief Technology Officer

Aug 24, 2020

UNION therapeutics A/S completes dosing of healthy volunteers with UNI911 (inhaled niclosamide) for COVID-19

Aug 13, 2020

UNION therapeutics A/S enters option agreement to acquire worldwide exclusive license for COVID-19 technologies developed by TFF Pharmaceuticals, Inc.

Jul 21, 2020

UNION therapeutics announces acquisition of PDE4i compound class from LEO Pharma with oral lead candidate (orismilast) in Phase 2